https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » United Kingdom
Mereo BioPharma begins BPS-804 mid-stage trial in osteogenesis imperfecta

Mereo BioPharma begins BPS-804 mid-stage trial in osteogenesis imperfecta

British specialty biopharma company Mereo BioPharma Group has wrapped up enrollment of patients for a phase 2b clinical trial that will evaluate its human monoclonal antibody BPS-804 (Setrusumab) as a potential treatment option for osteogenesis imperfecta (OI), better known as the brittle bone disease. Osteogenesis imperfecta is a rare, chronic genetic disorder that makes bones […]

Evox Therapeutics raises £35.5m to advance exosome therapeutics

Evox Therapeutics, an Oxford biotech spinout focused on developing exosome therapeutics, has raised £35.5 million from a Series B financing round led by Redmile Group with new investments from Google’s GV, Cowen Healthcare Investments and others. The Series B round of the UK biotechnology company also saw participation from existing investors – Oxford Sciences Innovation […]

Continue reading …
Gene therapy company Orchard Therapeutics raises $150m in new funding

Orchard Therapeutics, a UK and US based gene therapy company, has secured $150 million of new capital through a Series C funding round, towards advancing its gene therapies for rare diseases. Deerfield Management led the Series C round with other firms like RA Capital Management, Perceptive Advisors, Venrock and Foresite Capital making new investments in […]

Continue reading …
Britannia Pharmaceuticals apomorphine infusion succeeds in TOLEDO trial

Phase 3 trial for apomorphine infusion : British pharma company Britannia Pharmaceuticals said that its APO-go/MOVAPO (apomorphine) subcutaneous infusion has succeeded in a phase 3 trial called TOLEDO by delivering effective relief of persistent motor fluctuations in Parkinson’s disease. The TOLEDO trial saw apomorphine infusion given for 12 weeks in 107 Parkinson’s disease patients whose […]

Continue reading …
CHMP recommends AstraZeneca lung cancer drug Imfinzi EMA approval

Update on Imfinzi EMA approval : The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the approval of AstraZeneca lung cancer drug Imfinzi (durvalumab) for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC). The committee has recommended Imfinzi EMA approval of […]

Continue reading …